ABSTRACT SUBMISSION DEADLINE: April 4, 2022, at 11:59 PM EST. The American Heart Association maintains the highest standards in acceptance and program development.
Abstract Submission: Please submit all abstracts via email at firstname.lastname@example.org no later than 11:59PM on April 4, 2022.
Eligibility Requirements for Submission of Abstracts:
Fellows enrolled in a clinical training program
Residents enrolled in a clinical training program
Note: Non-tenured junior faculty are not eligible ot participate - only trainees. Also, individuals with a faculty appointment at the instructor level or higher are not eligible. Due to the anticipated volume of abstract submissions, there is a LIMIT OF (1) ABSTRACT SUBMISSION PER PERSON.
REGISTRATION IS FREE. The target of research can be anything broadly related to cardiovascular function and disease, including heart disease, vascular disease, and stroke. The range of disciplines appropriate for this event is BROAD and can include basic, translational, clinical, epidemiological, population, and bioengineering research. Participants may submit either of the following types of abstracts:
Identify major advances in key areas of cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology and arrhythmias.
Understand basic processes linking molecular and cellular biology and biochemistry with cardiovascular physiology and pathophysiology.
Recognize the promises and pitfalls of cell and gene therapy for cardiovascular disease.
Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.
Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke.
Note: If you do not know which category your abstract falls within, select 'Undeclared' on the abstract submission form and the Task Force will assign a category. Please follow the guidelines for abstract submission as outlined below:
Rules for Preparation and Submission of Abstracts
Fellows Research Day is an annual event designed to showcase the work of trainees in cardiovascular research.
Abstracts should be submitted from individuals currently in cardiovascular related training programs and students conducting cardiovascular related research.
Abstracts should be submitted for ongoing projects with preliminary data (not necessarily completed projects). Case reports will not be accepted.
The American Heart Association’s Fellows Research Day is a forum for the presentation of novel research findings. The work covered by the abstract must not have been published as a manuscript before the date and time of presentation. (January 17, 2020)
Previous presentations or acceptance of an abstract at a similar meeting does not preclude presentation at Fellow Research Day.
Abstract submission for Fellows Research Day does not preclude submission at national meetings.
Submission of an abstract constitutes a commitment by the Presenting Author to present it, if accepted.
Only electronic submissions will be accepted.
Due to the anticipated volume of abstract submissions, there is a limit of only (1) submission per person.
Expenses associated with the submission and presentation of an abstract are the responsibility of the presenter.
The Presenting Author is designated as the primary/submitting author. Fill in the information by typing into the boxes indicated.
Begin Other Author listing in the designated area. List first name, middle initial and last name of each author omitting degrees and titles.
You may rearrange the order of the authors; however, always list the senior author or mentor last.
Addition or deletions of author names are not permitted after 11:59 p.m., April 4, 2022.
Type of Abstract:
To ensure that your abstract receives proper scientific consideration, be sure to check off the appropriate category – Basic Science or Clinical Science. If unsure, check the box marked ‘Undeclared’ and the Fellows Research Day Task Force will determine the category.
An abstract must have a short, specific title that indicates the nature of the investigation. Use the title box provided on the form.
Do not use abbreviations in the title.
The title is limited to 250 characters. Spaces do not count as characters.
Submit all abstracts in English.
Authors should not “split” data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.
Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals will be disqualified.
To ensure that the abstract receives proper scientific consideration, please make sure that the abstract is submitted to the appropriate category.
Proofread abstracts carefully to avoid errors before submission. The abstract will be published exactly as it has been submitted.
In the abstract box, only provide the body of the abstract.
The abstract should contain the following headings in bold: Background, Hypothesis, Methods, Results and Conclusions.
Briefly describe objectives of the study unless they are contained in the title. Include a brief statement of methods if pertinent. State findings in detail sufficient to support conclusions.
Abstracts are limited to 1950 characters (about 300-350 words).
Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.
Use generic drug names.
Do not begin sentences with numerals.
Standard abbreviations may be used without definition. Nonstandard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word of phrase abbreviated.
Do not include references, credits or grant support.
Do not include the names or personal information of any patient participating in the study or trial.
After the April 4, 2022 deadline, abstracts may not be revised in any way or resubmitted. Proofread abstracts carefully to avoid errors before submission. If accepted, your abstract will be published as submitted.
Abstracts may be withdrawn by emailing the American Heart Association at email@example.com. However, there is no guarantee that the abstract may not be printed in the event’s program book.
Notification of acceptance of abstract will be emailed no later than April 18, 2022.
Instructions for oral or poster presentations will be provided upon acceptance.
- All oral presentations must be in electronic format - preferably Windows based.
- All presentations and question-and-answer sessions will be conducted in English.
- Presenters may request assistance from the moderator who will repeat or rephrase questions from the audience or may ask a colleague in the audience to assist with translation.
Unauthorized recording of the AHA Fellows Research Day sessions is prohibited, whether by video, still or digital photography, audio or any other recording or reproduction mechanism. This includes recording of presentations and supporting A/V materials and of poster presentations and supporting poster materials.
The AHA reserves the right to all video or audio recordings of presentations at Fellows Research Day.